4.5 Review

Current and Future Directions in Pediatric Allergic Rhinitis

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jaip.2013.03.012

关键词

Allergic rhinitis; Pediatrics; Specific immunotherapy; Intranasal corticosteroids; Antihistamines; Leukotriene modifiers

资金

  1. Merck
  2. Teva
  3. GlaxoSmithKline
  4. Sunovian
  5. Oxford Therapeutics
  6. Ono
  7. Britannia
  8. Meda
  9. Stallergenes
  10. Greer Laboratories
  11. Novartis
  12. Sunovion
  13. Istavision

向作者/读者索取更多资源

BACKGROUND: Allergic rhinitis (AR) is a common pediatric problem that significantly affects sleep, learning, performance, and quality of life. In addition, it is associated with significant comorbidities and complications. OBJECTIVE: The aim was to provide an update on the epidemiology, comorbidities, pathophysiology, current treatment, and future direction of pediatric AR. METHODS: Literature reviews in each of these areas were conducted, and the results were incorporated. RESULTS: The prevalence of AR is increasing in the pediatric population and is associated with significant morbidity, comorbidities, and complications. The mainstay of current treatment strategies includes allergen avoidance, pharmacotherapy, and allergen specific immunotherapy. CONCLUSIONS: In the future, diagnosis will be improved by microarrayed recombinant allergen testing and therapy will be expanded to include emerging treatments such as sublingual immunotherapy and combination products. (C) 2013 American Academy of Allergy, Asthma & Immunology

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据